Interleukin-6 in renal disease and therapy

Simon Arnett Jones, Donald James Fraser, Ceri Alan Fielding, Gareth Wyn Jones

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Interleukin (IL)-6 has become a major target for clinical intervention in various autoimmune conditions. Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes. During the course of this review, we will outline the biology surrounding IL-6 and discuss the impact of IL-6 in renal disease and the clinical complications associated with renal replacement therapies and transplantation. We will also consider the merit of IL-6 measurement as a prognostic indicator and provide a clinical perspective on IL-6-blocking therapies in renal disease.
Original languageEnglish
Pages (from-to)564-574
Number of pages11
JournalNephrology Dialysis Transplantation
Volume30
Issue number4
Early online date10 Jul 2014
DOIs
Publication statusPublished - Apr 2015

Fingerprint Dive into the research topics of 'Interleukin-6 in renal disease and therapy'. Together they form a unique fingerprint.

Cite this